Get the Stockscreener App
15.55
0.13%
0.02
After Hours:
15.55
Bausch Lomb Corp stock is traded at $15.55, with a volume of 211.78K.
It is up +0.13% in the last 24 hours and up +6.07% over the past month.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
See More
Previous Close:
$15.53
Open:
$15.47
24h Volume:
211.78K
Relative Volume:
0.40
Market Cap:
$5.51B
Revenue:
$4.89B
Net Income/Loss:
$-263.00M
P/E Ratio:
-20.11
EPS:
-0.7734
Net Cash Flow:
$-167.84M
1W Performance:
+4.08%
1M Performance:
+6.07%
6M Performance:
+36.40%
1Y Performance:
-23.21%
1-Day Range:
$15.30
$15.57
1-Week Range:
$14.60
$16.00
52-Week Range:
$10.45
$20.71
Bausch Lomb Corp Stock (BLCO) Company Profile
Name
Bausch Lomb Corp
Sector
Industry
Phone
908-541-5456
Address
520 APPLEWOOD CRESCENT, VAUGHAN
Compare BLCO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
15.55 | 5.50B | 4.89B | -263.00M | -167.84M | -0.7734 |
|
ISRG
Intuitive Surgical Inc
|
560.00 | 194.19B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
177.84 | 50.84B | 21.84B | 1.68B | 2.55B | 5.8322 |
|
RMD
Resmed Inc
|
251.49 | 36.44B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
ALC
Alcon Inc
|
73.97 | 36.72B | 10.03B | 1.07B | 1.39B | 2.1549 |
|
WST
West Pharmaceutical Services Inc
|
271.04 | 19.81B | 2.96B | 487.70M | 344.00M | 6.6758 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-01-25 | Initiated | Goldman | Neutral |
| May-02-25 | Reiterated | H.C. Wainwright | Buy |
| Mar-28-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-15-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-10-24 | Initiated | Raymond James | Outperform |
| May-06-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-12-23 | Initiated | Stifel | Hold |
| Oct-03-23 | Resumed | Evercore ISI | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Mar-09-23 | Initiated | Needham | Hold |
| Dec-21-22 | Initiated | Barclays | Equal Weight |
| Sep-12-22 | Initiated | H.C. Wainwright | Buy |
| Jul-26-22 | Initiated | RBC Capital Mkts | Outperform |
| Jun-24-22 | Initiated | Evercore ISI | Outperform |
| Jun-06-22 | Initiated | Citigroup | Buy |
| May-31-22 | Initiated | Deutsche Bank | Hold |
| May-31-22 | Initiated | Goldman | Neutral |
| May-31-22 | Initiated | Guggenheim | Buy |
| May-31-22 | Initiated | JP Morgan | Neutral |
| May-31-22 | Initiated | Jefferies | Buy |
| May-31-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-31-22 | Initiated | Wells Fargo | Overweight |
| May-11-22 | Initiated | Cowen | Outperform |
View All
Bausch Lomb Corp Stock (BLCO) Latest News
Will Pharmaceuticals Division Momentum and Updated Outlook Shift Bausch + Lomb's (BLCO) Investment Narrative? - Yahoo Finance
Can Bausch + Lomb Corporation stock resist sector downturnsQuarterly Growth Report & Free Safe Capital Growth Stock Tips - newser.com
Real time breakdown of Bausch + Lomb Corporation stock performanceWeekly Stock Analysis & Safe Capital Investment Plans - newser.com
What is the fair value estimate for Bausch + Lomb Corporation (S2L) stock in 2025Quarterly Profit Report & AI Enhanced Market Trend Forecasts - newser.com
Why Bausch + Lomb Corporation stock could see breakout soonTrade Volume Summary & Fast Exit Strategy with Risk Control - newser.com
Using data models to predict Bausch + Lomb Corporation stock movementQuarterly Market Review & Precise Trade Entry Recommendations - newser.com
Short interest data insights for Bausch + Lomb CorporationEntry Point & High Conviction Buy Zone Picks - newser.com
Earnings visualization tools for Bausch + Lomb CorporationGap Down & Fast Entry and Exit Trade Plans - newser.com
Why Bausch + Lomb Corporation stock is upgraded to buyJuly 2025 Analyst Calls & Real-Time Market Sentiment Reports - newser.com
Will Bausch + Lomb Corporation stock benefit from Fed rate cuts2025 Buyback Activity & Weekly Chart Analysis and Guides - newser.com
Is Bausch + Lomb Corporation (S2L) stock vulnerable to rate hikes2025 Winners & Losers & High Conviction Buy Zone Alerts - fcp.pa.gov.br
What margin trends mean for Bausch + Lomb Corporation stockQuarterly Market Summary & Real-Time Volume Analysis Alerts - newser.com
How strong is Bausch + Lomb Corporation stock revenue growthEarnings Miss & Real-Time Volume Triggers - newser.com
Is Bausch + Lomb Corporation stock safe for conservative investors2025 Year in Review & Real-Time Volume Analysis Alerts - newser.com
Needham maintains Hold rating on Bausch & Lomb stock ahead of Investor Day By Investing.com - Investing.com Canada
Needham Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating - 富途牛牛
Cautious Hold Rating for Bausch + Lomb Amid Market Position and Future Prospects - TipRanks
Published on: 2025-11-05 02:55:00 - newser.com
5 Revealing Analyst Questions From Bausch + Lomb’s Q3 Earnings Call - Yahoo Finance
Can Bausch + Lomb Corporation stock beat analyst upgradesJuly 2025 Trade Ideas & AI Based Buy/Sell Signal Reports - fcp.pa.gov.br
Full technical analysis of Bausch + Lomb Corporation stockWeekly Market Report & Precise Entry and Exit Recommendations - newser.com
Bausch + Lomb Brief: Says Will Hold an Investor Day on Thursday, Nov. 13, 2025, at the New York Stock Exchange - 富途牛牛
Bausch + Lomb (NYSE/TSX: BLCO) to hold Investor Day outlining 3-year plan and pipeline - Stock Titan
Bausch + Lomb to Hold Investor Day on Nov. 13 - MarketScreener
Bausch + Lomb to Hold Investor Day on Nov. 13 | Nation/World | bdtonline.com - Bluefield Daily Telegraph
Deutsche Bank Adjusts Price Target on Bausch + Lomb to $15 From $12, Maintains Hold Rating - MarketScreener
Bausch + Lomb price target raised to $14 from $12 at Stifel - MSN
Bausch + Lomb (NYSE:BLCO) Seems To Be Using A Lot Of Debt - 富途牛牛
Q4 EPS Estimates for Bausch + Lomb Raised by HC Wainwright - MarketBeat
Can Bausch + Lomb Corporation stock hit record highs againWeekly Trend Summary & High Return Trade Opportunity Guides - newser.com
Bausch + Lomb Corporation (NYSE:BLCO) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Forecasting Bausch + Lomb Corporation price range with options dataOptions Play & Step-by-Step Trade Execution Guides - newser.com
Bausch + Lomb (BLCO) Net Losses Deepen 53.3% Annually Despite Turnaround Hopes - Sahm
Bausch + Lomb (NYSE:BLCO) Given New $16.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Bausch & Lomb Is Maintained at Equal-Weight by Barclays - 富途牛牛
Bausch + Lomb's (BLCO) Outperform Rating Reaffirmed at Raymond James Financial - MarketBeat
A Quick Look at Today's Ratings for Bausch + Lomb Corp.(BLCO.US), With a Forecast Between $16 to $17 - 富途牛牛
HC Wainwright & Co. Maintains Bausch + Lomb (BLCO) Buy Recommendation - Nasdaq
7 Analysts Have This To Say About Bausch & Lomb - Benzinga
Barclays Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Raises Target Price to $17 - 富途牛牛
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bausch + Lomb Corporation (BLCO), United Therapeutics (UTHR) and Unicycive Therapeutics (UNCY) - The Globe and Mail
Bausch + Lomb Reports Q3 2025 Financial Results - The Globe and Mail
Bausch + Lomb Corporation (BLCO.TO) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Bausch & Lomb Corp (BLCO) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... By GuruFocus - Investing.com Canada
Bausch + Lomb Lifts Guidance After Beating Earnings Forecasts - Finimize
Bausch + Lomb Reports Q3 2025 Revenue Growth Amid Net Loss - MSN
J.P. Morgan Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Cuts Target Price to $16 - 富途牛牛
A Quick Look at Today's Ratings for Bausch + Lomb Corp.(BLCO.US), With a Forecast Between $13 to $17 - 富途牛牛
Bausch + Lomb price target raised to $16 from $15 at Wells Fargo - TipRanks
Bausch + Lomb Corporation (NYSE:BLCO) Q3 2025 Earnings Call Transcript - Insider Monkey
What Bausch + Lomb (BLCO)'s Strong Q3 Results and Pipeline Progress Mean For Shareholders - Sahm
Bausch Lomb Corp Stock (BLCO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):